View source for Drug project high-priority medications

<div style="width: 1px; height: 1px; background-color: #999999; position: fixed; top: 10px; left: 10px"></div><!---<div style="-webkit-user-select: none;">--->
__NOEDITSECTION____NOTOC__
<div style="text-align: center;">
<div style="float: left; padding: .5ex 0; font-weight: bold; background-color: #DFE0E1; border: 2px solid #a3b0bf; border-bottom: 0; font-size: 90%">&nbsp;&nbsp;&nbsp;[[Drug project|Mission Statement]]&nbsp;&nbsp;&nbsp;</div>
<div style="float: left; padding: .5ex 0; font-weight: bold; background-color: #DFE0E1; border: 2px solid #999; border-bottom: 0; border-left: 0; font-size: 90%">&nbsp;&nbsp;&nbsp;[[Drug project tutorial|Tutorial]]&nbsp;&nbsp;&nbsp;</div>
<div style="float: left; padding: .5ex 0; font-weight: bold; background-color: #DFE0E1; border: 2px solid #999; border-bottom: 0; border-left: 0; font-size: 90%">&nbsp;&nbsp;&nbsp;[[Drug project checklist|Editor's Checklist]]&nbsp;&nbsp;&nbsp;</div>
<div style="float: left; padding: .5ex 0; font-weight: bold; background-color: #DFE0E1; border: 2px solid #999; border-bottom: 0; border-left: 0; font-size: 90%">&nbsp;&nbsp;&nbsp;[[Drug project list of medications|List of Medications]]&nbsp;&nbsp;&nbsp;</div>
<div style="float: left; padding: .5ex 0; font-weight: bold; background-color: #CEDFF2; border: 2px solid #999; border-bottom: 0; border-left: 0; font-size: 90%">&nbsp;&nbsp;&nbsp;[[Drug project high-priority medications|High-Priority Medications]]&nbsp;&nbsp;&nbsp;</div>
</div>
<div style="clear:both; width: 95%; border: 3px solid #999; padding: 1em 1em;">
==WikiDoc Drug Project — High-Priority Medications==

*Template here: [[Drug page template]]
*Example here: [[Clopidogrel]]
*FDA package insert here: [https://dailymed.nlm.nih.gov/dailymed/ DailyMed]

==List of high-priority medications==

=== Novel Drug Approvals for 2023 ===
{| class="wikitable"
! No. !! Drug Name !! Active Ingredient !! Approval Date !! FDA-approved use on approval date
|-
|55
|Wainua
|eplontersen
|12/21/2023
|To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
|-
|54
|Filsuvez
|birch triterpenes
|12/18/2023
|To treat wounds associated with dystrophic and junctional epidermolysis bullosa
|-
| 53 || Fabhalta || iptacopan || 12/5/2023 || To treat paroxysmal nocturnal hemoglobinuria
|-
| 52 || Ogsiveo || nirogacestat || 11/27/2023 || To treat adults with progressing desmoid tumors who require systemic treatment
|-
| 51 || Truqap || capivasertib || 11/16/2023 || To treat breast cancer that meets certain disease criteria
|-
| 50 || Ryzneuta || efbemalenograstim alfa-vuxw || 11/16/2023 || To treat neutropenia
|-
| 49 || Augtyro || repotrectinib || 11/15/2023 || To treat ROS1-positive non-small cell lung cancer
|-
| 48 || Defencath || taurolidine, heparin || 11/15/2023 || To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter
|-
| 47 || Fruzaqla || fruquintinib || 11/08/23 || To treat refractory, metastatic colorectal cancer
|-
| 46 || Loqtorzi || toripalimab-tpzi || 10/27/2023 || To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies
|-
| 45 || Omvoh || mirikizumab-mrkz || 10/26/2023 || To treat ulcerative colitis
|-
| 44 || Agamree || vamorolone || 10/26/2023 || To treat Duchenne muscular dystrophy
|-
| 43 || Bimzelx || bimekizumab || 10/17/2023 || To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
|-
| 42 || Zilbrysq || zilucoplan || 10/17/2023 || To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive
|-
| 41 || Velsipity || etrasimod || 10/12/23 || To treat moderately to severely active ulcerative colitis in adults
|-
| 40 || Rivfloza || nedosiran || 9/29/2023 || To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function
|-
| 39 || Pombiliti || cipaglucosidase alfa-atga || 9/28/2023 || To treat late-onset Pompe disease
|-
| 38 || Exxua || gepirone || 9/22/2023 || To treat major depressive disorder
|-
| 37 || Ojjaara || momelotinib || 9/15/2023 || To treat intermediate or high-risk myelofibrosis in adults with anemia
|-
| 36 || Aphexda || motixafortide || 09/08/23 || To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma
|-
| 35 || Veopoz || pozelimab-bbfg || 8/18/2023 || To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease
|-
| 34 || Sohonos || palovarotene || 8/16/2023 || To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva
|-
| 33 || Elrexfio || elranatamab-bcmm || 8/14/2023 || To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy
|-
| 32 || Talvey || talquetamab-tgvs || 08/09/23 || To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies
|-
| 31 || Izervay || avacincaptad pegol || 08/04/23 || To treat geographic atrophy secondary to age-related macular degeneration
|-
| 30 || Zurzuvae || zuranolone || 08/04/23 || To treat postpartum depression 
|-
| 29 || Xdemvy || lotilaner || 7/25/2023 || To treat Demodex blepharitis
|-
| 28 || Vanflyta || quizartinib || 7/20/2023 || To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria
|-
| 27 || Beyfortus || nirsevimab-alip || 7/17/2023 || To prevent respiratory syncytial virus (RSV) lower respiratory tract disease
|-
| 26 || Ngenla || somatrogon-ghla || 6/27/2023 || To treat growth failure due to inadequate secretion of endogenous growth hormone
|-
| 25 || Rystiggo || rozanolixizumab-noli || 6/26/2023 || To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive
|-
| 24 || Litfulo || ritlecitinib || 6/23/2023 || To treat severely patchy hair loss
|-
| 23 || Columvi || glofitamab-gxbm || 6/15/2023 || To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy
|-
| 22 || Inpefa || sotagliflozin || 5/26/2023 || To treat heart failure 
|-
| 21 || Posluma || flotufolastat F 18 || 5/25/2023 || To use with positron emission tomography imaging in certain patients with prostate cancer
|-
| 20 || Paxlovid || nirmatrelvir, ritonavir || 5/25/2023 || To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19
|-
| 19 || Xacduro || sulbactam, durlobactam || 5/23/2023 || To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex
|-
| 18 || Epkinly || epcoritamab-bysp || 5/19/2023 || To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy
|-
| 17 || Miebo || perfluorhexyloctane || 5/18/2023 || To treat signs and symptoms of dry eye disease
|-
| 16 || Veozah || fezolinetant || 05/12/23 || To treat moderate to severe hot flashes caused by menopause
|-
| 15 || Elfabrio || pegunigalsidase alfa-iwxj || 05/09/23 || To treat confirmed Fabry disease
|-
| 14 || Qalsody || tofersen || 4/25/2023 || To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation
|-
| 13 || Joenja || leniolisib || 3/24/2023 || To treat activated phosphoinositide 3-kinase delta syndrome
|-
| 12 || Rezzayo || rezafungin || 3/22/2023 || To treat candidemia and invasive candidiasis
|-
| 11 || Zynyz || retifanlimab-dlwr || 3/22/2023 || To treat metastatic or recurrent locally advanced Merkel cell carcinoma
|-
| 10 || Daybue || trofinetide || 03/10/23 || To treat Rett syndrome
|-
| 9 || Zavzpret || zavegepant || 03/09/23 || To treat migraine
|-
|8
|Skyclarys
|omaveloxolone
|2/28/2023
|To treat Friedrich’s ataxia
|-
|7
|Filspari
|sparsentan
|2/17/2023
|To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
|-
|6
|Lamzede
|velmanase alfa-tycv
|2/16/2023
|To treat non-central nervous system manifestations of alpha-mannosidosis
|-
|5
|Jesduvroq
|daprodustat
|02/01/23
|To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months
|-
|4
|Orserdu
|elacestrant 
|1/27/2023
|To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
|-
|3
|Jaypirca
|pirtobrutinib
|1/27/2023
|To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor 
|-
|2
|Brenzavvy
|bexagliflozin
|1/20/2023
|To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
|-
|1
|Leqembi
|lecanemab-irmb
|01/06/23
|To treat Alzheimer’s disease
|}

===Novel Drug Approvals for 2022===

{| class="wikitable"
! No. !! Drug Name !! Active Ingredient !! Approval Date !! FDA-approved use on approval date
|-
| 37 || NexoBrid || anacaulase-bcdb || 12/28/2022 || To remove eschar in adults with deep partial thickness or full thickness thermal burns
|-
| 36 || Briumvi || ublituximab-xiiy || 12/28/2022 || To treat relapsing forms of multiple sclerosis
|-
| 35 || Xenoview || hyperpolarized Xe-129 || 12/23/2022 || To evaluate pulmonary function and imaging
|-
| 34 || Lunsumio || mosunetuzumab-axgb || 12/22/2022 || To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma
|-
| 33 || Sunlenca || lenacapavir || 12/22/2022 || To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerationsPress Release
|-
| 32 || Krazati || adagrasib || 12/12/2022 || To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy
|-
| 31 || Rezlidhia || olutasidenib || 12/1/2022 || To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation
|-
| 30 || Tzield || teplizumab-mzwv || 11/18/22 || To delay the onset of stage 3 type 1 diabetesPress Release
|-
| 29 || Elahere || mirvetuximab soravtansine-gynx || 11/14/2022 || To treat patients with recurrent ovarian cancer that is resistant to platinum therapy
|-
| 28 || Tecvayli || teclistamab-cqyv || 10/25/2022 || To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy
|-
| 27 || Imjudo || tremelimumab || 10/21/2022 || To treat unresectable hepatocellular carcinoma
|-
| 26 || Lytgobi || futibatinib || 9/30/2022 || To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
|-
| 25 || Relyvrio || sodium phenylbutyrate/taurursodiol || 9/29/2022 || To treat amyotrophic lateral sclerosis (ALS)Press Release
|-
| 24 || Omlonti || oomidenepag isopropyl ophthalmic solution || 9/22/2022 || To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension
|-
| 23 || Elucirem || gadopiclenol || 9/21/2022 || To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body
|-
| 22 || Terlivaz || terlipressin || 9/14/2022 || To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
|-
| 21 || Rolvedon || eflapegrastim || 9/9/2022 || To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia
|-
| 20 || Sotyktu || deucravacitinib || 9/9/2022 || To treat moderate-to-severe plaque psoriasis
|-
| 19 || Daxxify || daxibotulinumtoixnA-lanm || 9/7/2022 || To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity
|-
| 18 || Spevigo || spesolimab-sbzo || 9/1/2022 || To treat generalized pustular psoriasis flares
|-
| 17 || Xenpozyme || Olipudase alfa || 8/31/2022 || To treat Acid Sphingomyelinase DeficiencyPress Release
|-
| 16 || Amvuttra || vutrisiran || 6/13/2022 || To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
|-
| 15 || Vtama || tapinarof || 5/23/2022 || To treat plaque psoriasis
|-
| 14 || Mounjaro || tirzepatide || 5/13/2022 || To improve blood sugar control in diabetes, in addition to diet and exercise Press Release
|-
| 13 || Voquezna || vonoprazan, amoxicillin, and clarithromycin || 5/3/2022 || To treat Helicobacter pylori infection
|-
| 12 || Camzyos || mavacamten || 4/28/2022 || To treat certain classes of obstructive hypertrophic cardiomyopathy
|-
| 11 || Vivjoa || oteseconazole || 4/26/2022 || To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential
|-
| 10 || Pluvicto || lutetium (177Lu) vipivotide tetraxetan || 3/23/2022 || To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies
|-
| 9 || Opdualag || nivolumab and relatlimab-rmbw || 3/18/2022 || To treat unresectable or metastatic melanoma
|-
| 8 || Ztalmy || ganaxolone || 3/18/2022 || To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder
|-
| 7 || Vonjo || pacritinib || 2/28/2022 || To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets
|-
| 6 || Pyrukynd || mitapivat || 2/17/2022 || To treat hemolytic anemia in pyruvate kinase deficiency
|-
| 5 || Enjaymo || sutimlimab-jome || 2/4/2022 || To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease
|-
| 4 || Vabysmo || faricimab-svoa || 1/28/2022 || To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema
|-
| 3 || Kimmtrak || tebentafusp-tebn || 1/25/2022 || To treat unresectable or metastatic uveal melanoma 
|-
| 2 || Cibinqo || abrocitinib || 1/14/2022 || To treat refractory, moderate-to-severe atopic dermatitis
|-
| 1 || Quviviq || daridorexant || 1/7/2022 || To treat insomnia
|}

===Novel Drug Approvals for 2021===

{| class="wikitable"
! No. !! Drug Name !! Active Ingredient !! Approval Date !! FDA-approved use on approval date
|-
| 42 || Scemblix || asciminib || 10/29/2021 || To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteria
|-
| 41 || Tavneos || avacopan || 10/7/2021 || To treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy, including glucocorticoids
|-
| 40 || Livmarli || maralixibat || 9/29/2021 || To treat cholestatic pruritus associated with Alagille syndrome
|-
| 39 || Qulipta || atogepant || 9/28/2021 || To prevent episodic migraines
|-
| 38 || Tivdak || tisotumab vedotin-tftv || 9/20/2021 || To treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
|-
| 37 || Exkivity || mobocertinib || 9/15/2021 || To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations
|-
| 36 || Skytrofa || lonapegsomatropin-tcgd || 8/25/2021 || To treat short stature due to inadequate secretion of endogenous growth hormone
|-
| 35 || Korsuva || difelikefalin || 8/23/2021 || To treat moderate-to-severe pruritus associated with chronic kidney disease in certain populations
|-
| 34 || Welireg || belzutifan || 8/13/2021 || To treat von Hippel-Lindau disease under certain conditions
|-
| 33 || Nexviazyme || avalglucosidase alfa-ngpt || 8/6/2021 || To treat late-onset Pompe disease
|-
| 32 || Saphnelo || anifrolumab-fnia || 7/30/2021 || To treat moderate-to severe systemic lupus erythematousus along with standard therapy
|-
| 31 || Bylvay || odevixibat || 7/20/2021 || To treat pruritus
|-
| 30 || Rezurock || belumosudil || 7/16/2021 || To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy
|-
| 29 || fexinidazole || fexinidazole || 7/16/2021 || To treat human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense
|-
| 28 || Kerendia || finerenone || 7/9/2021 || To reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes
|-
| 27 || Rylaze || asparaginase erwinia chrysanthemi (recombinant)-rywn || 6/30/2021 || To treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimen
|-
| 26 || Aduhelm || aducanumab-avwa || 6/7/2021 || To treat Alzheimer’s disease
|-
| 25 || Brexafemme || ibrexafungerp || 6/1/2021 || To treat vulvovaginal candidiasis
|-
| 24 || Lybalvi || olanzapine and samidorphan || 5/28/2021 || To treat schizophrenia and certain aspects of bipolar I disorder
|-
| 23 || Truseltiq || infigratinib || 5/28/2021 || To treat cholangiocarcinoma whose disease meets certain criteria
|-
| 22 || Lumakras || sotorasib || 5/28/2021 || To treat types of non-small cell lung cancer
|-
| 21 || Pylarify || piflufolastat F 18 || 5/26/2021 || To identify prostate-specific membrane antigen-positive lesions in prostate cancer
|-
| 20 || Rybrevant || amivantamab-vmjw || 5/21/2021 || To treat a subset of non-small cell lung cancer
|-
| 19 || Empaveli || pegcetacoplan || 5/14/2021 || To treat paroxysmal nocturnal hemoglobinuria
|-
| 18 || Zynlonta || loncastuximab tesirine-lpyl || 4/23/2021 || To treat certain types of relapsed or refractory large B-cell lymphoma
|-
| 17 || Jemperli || dostarlimab-gxly || 4/22/2021 || To treat endometrial cancer
|-
| 16 || Nextstellis || drospirenone and estetrol || 4/15/2021 || To prevent pregnancy
|-
| 15 || Qelbree || viloxazine || 4/2/2021 || To treat attention deficit hyperactivity disorder
|-
| 14 || Zegalogue || dasiglucagon || 3/22/2021 || To treat severe hypoglycemia
|-
| 13 || Ponvory || ponesimod || 3/18/2021 || To treat relapsing forms of multiple sclerosis
|-
| 12 || Fotivda || tivozanib || 3/10/2021 || To treat renal cell carcinoma
|-
| 11 || Azstarys || serdexmethylphenidate and dexmethylphenidate || 3/2/2021 || To treat attention deficit hyperactivity disorder
|-
| 10 || Pepaxto || melphalan flufenamide || 2/26/2021 || To treat relapsed or refractory multiple myeloma
|-
| 9 || Nulibry || fosdenopterin || 2/26/2021 || To reduce the risk of mortality in molybdenum cofactor deficiency Type A
|-
| 8 || Amondys 45 || casimersen || 2/25/2021 || To treat Duchenne muscular dystrophy
|-
| 7 || Cosela || trilacicilib || 2/12/2021 || To mitigate chemotherapy-induced myelosuppression in small cell lung cancer
|-
| 6 || Evkeeza || evinacumab-dgnb || 2/11/2021 || To treat homozygous familial hypercholesterolemia
|-
| 5 || Ukoniq || umbralisib || 2/5/2021 || To treat marginal zone lymphoma and follicular lymphoma
|-
| 4 || Tepmetko || tepotinib || 2/3/2021 || To treat non-small cell lung cancer
|-
| 3 || Lupkynis || voclosporin || 1/22/2021 || To treat lupus nephritis
|-
| 2 || Cabenuva || cabotegravir and rilpivirine (co-packaged) || 1/21/2021 || To treat HIV
|-
| 1 || Verquvo || vericiguat || 1/19/2021 || To mitigate the risk of cardiovascular death and hospitalization for chronic heart failure
|}

===Novel Drug Approvals for 2020===

{| class="wikitable"
! No. !! Drug Name !! Active Ingredient !! Approval Date !! FDA-approved use on approval date
|-
| 53 || Gemtesa || vibegron || 12/23/2020 || To treat overactive bladder
|-
| 52 || Ebanga || ansuvimab-zykl || 12/21/2020 || To treat ebola
|-
| 51 || Orgovyx || relugolix || 12/18/2020 || To treat advanced prostate cancer
|-
| 50 || Margenza || margetuximab (anti-HER2 mAb || 12/16/2020 || To treat HER2+ breast cancer
|-
| 49 || Klisyri || tirbanibulin || 12/14/2020 || To treat actinic Keratosis of the face or scalp
|-
| 48 || Orladeyo || berotralstat || 12/3/2020 || To treat patients with hereditary angioedema
|-
| 47 || Gallium 68 PSMA-11 || Gallium 68 PSMA-11 || 12/1/2020 || For detection and localization of prostate cancer
|-
| 46 || Danyelza || naxitamab-gqgk || 11/25/2020 || To treat high-risk refractory or relapsed neuroblastoma
|-
| 45 || Imcivree || setmelanotide || 11/25/2020 || To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age
|-
| 44 || Oxlumo || lumasiran || 11/23/2020 || To treat hyperoxaluria type 1
|-
| 43 || Zokinvy || lonafarnib || 11/20/2020 || To treat rare conditions related to premature aging
|-
| 42 || Veklury || remdesivir || 10/22/2020 || To treat COVID-19
|-
| 41 || Inmazeb || atoltivimab, maftivimab, and odesivimab-ebgn || 10/14/2020 || To treat ebola virus
|-
| 40 || Gavreto || pralsetinib || 9/4/2020 || To treat non-small lung cancer
|-
| 39 || Detectnet || copper Cu 64 dotatate injection || 9/3/2020 || To help detect certain types of neuroendocrine tumors
|-
| 38 || Sogroya || somapacitan-beco || 8/28/2020 || Growth hormone
|-
| 37 || Winlevi || clascoterone || 8/26/2020 || To treat acne
|-
| 36 || Enspryng || satralizumab-mwge || 8/14/2020 || To treat neuromyelitis optica spectrum disorder
|-
| 35 || Viltepso || viltolarsen || 8/12/2020 || To treat Duchenne muscular dystrophy
|-
| 34 || Olinvyk || oliceridine || 8/7/2020 || To manage acute pain in certain adults
|-
| 33 || Evrysdi || risdiplam || 8/7/2020 || To treat spinal muscular atrophy
|-
| 32 || Lampit || nifurtimox || 8/6/2020 || To treat Chagas disease in certain pediatric patients younger than age 18
|-
| 31 || Blenrep || belantamab mafodotin-blmf || 8/5/2020 || To treat multiple myeloma
|-
| 30 || Monjuvi || tafasitamab-cxix || 7/31/2020 || To treat relapsed or refractory diffuse large B-cell lymphoma
|-
| 29 || Xeglyze || abametapir || 7/24/2020 || To treat head lice
|-
| 28 || Inqovi || decitabine and cedazuridine || 7/7/2020 || To treat adult patients with myelodysplastic syndromes
|-
| 27 || Rukobia || fostemsavir || 7/2/2020 || To treat HIV
|-
| 26 || Byfavo || remimazolam || 7/2/2020 || For sedation
|-
| 25 || Dojolvi || triheptanoin || 6/30/2020 || To treat molecularly long-chain fatty acid oxidation disorders
|-
| 24 || Zepzelca || lurbinectedin || 6/15/2020 || To treat metastatic small cell lung cancer
|-
| 23 || Uplizna || inebilizumab-cdon || 6/11/2020 || To treat neuromyelitis optica spectrum disorder
|-
| 22 || Tauvid || flortaucipir F18 || 5/28/2020 || Diagnostic agent for patients with Alzheimer’s disease
|-
| 21 || Artesunate || artesunate || 5/26/2020 || To treat severe malaria
|-
| 20 || Cerianna || fluoroestradiol F18 || 5/20/2020 || Diagnostic imaging agent for certain patients with breast cancer
|-
| 19 || Qinlock || ripretinib || 5/15/2020 || To treat advanced gastrointestinal-stromal tumors
|-
| 18 || Retevmo || selpercatinib || 5/8/2020 || To treat lung and thyroid cancers
|-
| 17 || Tabrecta || capmatinib || 5/6/2020 || To treat patients with non small cell lung cancer
|-
| 16 || Ongentys || opicapone || 4/24/2020 || To treat patients with Parkinson’s disease experiencing “off” episodes
|-
| 15 || Trodelvy || sacituzumab govitecan-hziy || 4/22/2020 || To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease
|-
| 14 || Pemazyre || pemigatinib || 4/17/2020 || To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts
|-
| 13 || Tukysa || tucatinib || 4/17/2020 || To treat advanced unresectable or metastatic HER2-positive breast cancer
|-
| 12 || Koselugo || selumetinib || 4/10/2020 || To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves
|-
| 11 || Zeposia || ozanimod || 3/25/2020 || To treat relapsing forms of multiple sclerosis
|-
| 10 || Isturisa || osilodrostat || 3/6/2020 || To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease
|-
| 9 || Sarclisa || isatuximab || 3/2/2020 || To treat multiple myloma
|-
| 8 || Nurtec ODT || rimegepant || 2/27/2020 || To treat migraine
|-
| 7 || Barhemsys || amisulpride || 2/26/2020 || To help prevent nausea and vomiting after surgery
|-
| 6 || Vyepti || eptinezumab-jjmr || 2/21/2020 || For the preventive treatment of migraine in adults
|-
| 5 || Nexletol || bempedoic acid || 2/21/2020 || To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C
|-
| 4 || Pizensy || lactitol || 2/12/2020 || To treat chronic idiopathic constipation (CIC) in adults
|-
| 3 || Tazverik || tazemetostat || 1/23/2020 || To treat epithelioid sarcoma
|-
| 2 || Tepezza || teprotumumab-trbw || 1/21/2020 || To treat Thyroid eye disease
|-
| 1 || Ayvakit || avapritinib || 1/9/2020 || To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST)
|}

===Novel Drug Approvals for 2019===

{| class="wikitable"
! No. !! Drug Name !! Active Ingredient !! Approval Date !! FDA-approved use on approval date
|-
| 48 || Ubrelvy || ubrogepant || 12/23/2019 || to treat acute treatment of migraine with or without aura in adults
|-
| 47 || Enhertu || fam-trastuzumab deruxtecan-nxki || 12/20/2019 || To treat metastatic breast cancer
|-
| 46 || Dayvigo || lemborexant || 12/20/2019 || To treat insomnia
|-
| 45 || Caplyta || lumateperone tosylate || 12/20/2019 || To treat schizophrenia
|-
| 44 || TissueBlue || Brilliant Blue G Ophthalmic Solution || 12/20/2019 || Dye used in eye surgery
|-
| 43 || Padcev || enfortumab vedotin-ejfv || 12/18/2019 || To treat refractory bladder cancer
|-
| 42 || Vyondys 53 || golodirsen || 12/12/2019 || To treat certain patients with Duchenne muscular dystrophy
|-
| 41 || Oxbryta || voxelotor || 11/25/2019 || To treat sickle cell disease
|-
| 40 || Xcopri || cenobamate || 11/21/2019 || To treat partial onset seizures
|-
| 39 || Givlaari || givosiran || 11/20/2019 || To treat acute hepatic porphyria, a rare blood disorder
|-
| 38 || Adakveo || crizanlizumab-tmca || 11/15/2019 || To treat patients with painful complication of sickle cell disease
|-
| 37 || Fetroja || cefiderocol || 11/14/2019 || To treat patients with complicated urinary tract infections who have limited or no alternative treatment options
|-
| 36 || Brukinsa || zanubrutinib || 11/14/2019 || To treat certain patients with mantle cell lymphoma, a form of blood cancer
|-
| 35 || Reblozyl || luspatercept–aamt || 11/8/2019 || For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions
|-
| 34 || ExEm Foam || air polymer-type A || 11/7/2019 || A diagnostic agent used to assess fallopian tube patency (openness) in women with known or suspected infertility
|-
| 33 || Trikafta || elexacaftor/ivacaftor/tezacaftor || 10/21/2019 || To treat patients 12 years of age and older with the most common gene mutation that causes cystic fibrosis
|-
| 32 || Reyvow || lasmiditan || 10/11/2019 || For the acute treatment of migraine with or without aura, in adults
|-
| 31 ||  || fluorodopa F 18 || 10/10/2019 || A diagnostic agent for use in positron emission tomography (PET) to help diagnose adult patients with suspected Parkinsonian syndromes (PS)
|-
| 30 || Scenesse || afamelanotide || 10/8/2019 || To increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria
|-
| 29 || Beovu || brolucizumab–dbll || 10/7/2019 || Treatment of wet age-related macular degeneration
|-
| 28 || Aklief || trifarotene || 10/4/2019 || For the topical treatment of acne vulgaris in patients 9 years of age and older
|-
| 27 || Ibsrela || tenapanor || 9/12/2019 || To treat irritable bowel syndrome with constipation in adults.
|-
| 26 || Nourianz || istradefylline || 8/27/2019 || To treat adult patients with Parkinson’s disease experiencing “off” episodes
|-
| 25 || Ga-68-DOTATOC || Ga-68-DOTATOC || 8/21/2019 || For use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs)
|-
| 24 || Xenleta || lefamulin || 8/19/2019 || To treat adults with community-acquired bacterial pneumonia
|-
| 23 || Rinvoq || upadacitinib || 8/16/2019 || To treat adults with moderately to severely active rheumatoid arthritis
|-
| 22 || Inrebic || fedratinib || 8/16/2019 || To treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
|-
| 21 || Rozlytrek || entrectinib || 8/15/2019 || To treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive
|-
| 20 || Wakix || pitolisant || 8/14/2019 || To treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy
|-
| 19 ||  || pretomanid || 8/14/2019 || For treatment-resistant forms of tuberculosis that affects the lungs
|-
| 18 || Turalio || pexidartinib || 8/2/2019 || To treat adult patients with symptomatic tenosynovial giant cell tumor
|-
| 17 || Nubeqa || darolutamide || 7/30/2019 || To treat adult patients with non-metastatic castration resistant prostate cancer
|-
| 16 || Accrufer || ferric maltol || 7/25/2019 || To treat iron deficiency anemia in adults
|-
| 15 || Recarbrio || imipenem, cilastatin and relebactam || 7/16/2019 || To treat complicated urinary tract and complicated intra-abdominal infections
|-
| 14 || Xpovio || selinexor || 7/3/2019 || To treat adult patients with relapsed or refractory multiple myeloma (RRMM)
|-
| 13 || Vyleesi || bremelanotide || 6/21/2018 || To treat hypoactive sexual desire disorder in premenopausal women.
|-
| 12 || Polivy || polatuzumab vedotin-piiq || 6/10/2019 || To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma
|-
| 11 || Piqray || alpelisib || 5/24/2019 || To treat breast cancer
|-
| 10 || Vyndaqel || tafamidis meglumine || 5/3/2019 || To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults
|-
| 9 || Skyrizi || risankizumab-rzaa || 4/23/2019 || To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
|-
| 8 || Balversa || erdafitinib || 4/12/2019 || To treat adult patients with locally advanced or metastatic bladder cancer
|-
| 7 || Evenity || romosozumab-aqqg || 4/9/2019 || To treat osteoporosis in postmenopausal women at high risk of fracture
|-
| 6 || Mayzent || siponimod || 3/26/2019 || To treat adults with relapsing forms of multiple sclerosis
|-
| 5 || Sunosi || solriamfetol || 3/20/2019 || To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
|-
| 4 || Zulresso || brexanolone || 3/19/2019 || To treat postpartum depression (PPD) in adult women
|-
| 3 || Egaten || triclabendazole || 2/13/2019 || To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”
|-
| 2 || Cablivi || caplacizumab-yhdp || 2/6/2019 || To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP)
|-
| 1 || Jeuveau || prabotulinumtoxinA-xvfs || 2/1/2019 || For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients
|}

<!---
{| class="wikitable"
| align="center" style="background:#f0f0f0;" |'''Year'''
| align="center" style="background:#f0f0f0;" |'''No.'''
| align="center" style="background:#f0f0f0;" |'''Brand Name'''
| align="center" style="background:#f0f0f0;" |'''Active Ingredient'''
| align="center" style="background:#f0f0f0;" |'''Page Link'''
| align="center" style="background:#f0f0f0;" |'''DailyMed Search'''
| align="center" style="background:#f0f0f0;" |'''Approval Date'''
| align="center" style="background:#f0f0f0;" |'''Status'''
| align="center" style="background:#f0f0f0;" |'''Author'''
|-
|2019||12||Polivy||Polatuzumab vedotin-piiq||[[Polatuzumab vedotin-piiq]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Polivy Polivy]||6/10/2019
|
|
|-
|2019||11||Piqray||Alpelisib||[[Alpelisib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Piqray Piqray]||5/24/2019
|Needs review
|Uma Maveli
|-
|2019||10||Vyndaqel||Tafamidis meglumine||[[Tafamidis meglumine]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vyndaqel Vyndaqel]||5/3/2019
|
|
|-
|2019||9||Skyrizi||Risankizumab||[[Risankizumab]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Skyrizi Skyrizi]||4/23/2019
|
|
|-
|2019||8||Balversa||Erdafitinib||[[Erdafitinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Balversa Balversa]||4/12/2019
|
|
|-
|2019||7||Evenity||Romosozumab||[[Romosozumab]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Evenity Evenity]||4/9/2019
|
|
|-
|2019||6||Mayzent||Siponimod||[[Siponimod]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Mayzent Mayzent]||3/26/2019
|
|
|-
|2019||5||Sunosi||Solriamfetol||[[Solriamfetol]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sunosi Sunosi]||3/20/2019
|
|
|-
|2019||4||Zulresso||Brexanolone||[[Brexanolone]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Zulresso Zulresso]||3/19/2019
|
|
|-
|2019||3||Egaten||Triclabendazole||[[Triclabendazole]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Egaten Egaten]||2/13/2019
|
|
|-
|2019||2||Cablivi||Caplacizumab||[[Caplacizumab]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cablivi Cablivi]||2/6/2019
|
|
|-
|2019||1||Jeuveau||prabotulinum toxin type a powder||[[prabotulinum toxin type a powder]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Jeuveau Jeuveau]||2/1/2019
|
|
|-
|2018||59||Ultomiris||Ravulizumab||[[Ravulizumab]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ultomiris Ultomiris]||12/21/2018
|Needs review
|Bhavya
|-
|2018||58||Elzonris||Tagraxofusp-erzs||[[Tagraxofusp-erzs]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Elzonris Elzonris]||12/21/2018
|
|
|-
|2018||57||Asparlas||Calaspargase pegol-mknl||[[Calaspargase pegol-mknl]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Asparlas Asparlas]||12/20/2018
|
|
|-
|2018||56||Motegrity||Prucalopride||[[Prucalopride]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Motegrity Motegrity]||12/14/2018
|
|
|-
|2018||55||Xospata||Gilteritinib||[[Gilteritinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Xospata Xospata]||11/28/2018
|Needs review
|Uma Maveli
|-
|2018||54||Firdapse||Amifampridine||[[Amifampridine]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Firdapse Firdapse]||11/28/2028
|
|
|-
|2018||53||Vitrakvi||Larotrectinib||[[Larotrectinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vitrakvi Vitrakvi]||11/26/2018
|
|
|-
|2018||52||Daurismo||Glasdegib||[[Glasdegib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Daurismo Daurismo]||11/21/2018
|Need review
|Bhavya
|-
|2018||51||Gamifant||Emapalumab-lzsgemapalumab-lzsg||[[Emapalumab-lzsgemapalumab-lzsg]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Gamifant Gamifant]||11/20/2018
|
|
|-
|2018||50||Aemcolo||Rifamycin||[[Rifamycin]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Aemcolo Aemcolo]||11/16/2018
|
|
|-
|2018||49||Yupelri||Revefenacin||[[Revefenacin]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Yupelri Yupelri]||11/9/2018
|Needs review
|Uma Maveli
|-
|2018||48||Lorbrena||Lorlatinib||[[Lorlatinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lorbrena Lorbrena]||11/2/2018
|Needs review
|Uma Maveli
|-
|2018||47||Xofluza||Baloxavir marboxil||[[Baloxavir marboxil]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Xofluza Xofluza]||10/24/2018
|
|
|-
|2018||46||Talzenna||Talazoparib||[[Talazoparib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Talzenna Talzenna]||10/16/2018
|
|
|-
|2018||45||Tegsedi||Inotersen||[[Inotersen]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tegsedi Tegsedi]||10/5/2018
|
|
|-
|2018||44||Revcovi||Elapegademase-lvlr||[[Elapegademase-lvlr]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Revcovi Revcovi]||10/5/2018
|
|
|-
|2018||43||Nuzyra||Omadacycline||[[Omadacycline]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Nuzyra Nuzyra]||10/2/2018
|
|
|-
|2018||42||Seysara||Sarecycline||[[Sarecycline]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Seysara Seysara]||10/1/2018
|
|
|-
|2018||41||Libtayo||Cemiplimab-rwlc||[[Cemiplimab-rwlc]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Libtayo Libtayo]||9/28/2018
|
|
|-
|2018||40||Vizimpro||Dacomitinib||[[Dacomitinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vizimpro Vizimpro]||9/27/2018
|
|
|-
|2018||39||Emgality||Galcanezumab-gnlm||[[Galcanezumab-gnlm]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Emgality Emgality]||9/27/2018
|
|
|-
|2018||38||Copiktra||Duvelisib||[[Duvelisib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Copiktra Copiktra]||9/24/2018
|
|
|-
|2018||37||Ajovy||Fremanezumab-vfrm||[[Fremanezumab-vfrm]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ajovy Ajovy]||9/14/2018
|
|
|-
|2018||36||Lumoxiti||Moxetumomab pasudotox-tdfk||[[Moxetumomab pasudotox-tdfk]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lumoxiti Lumoxiti]||9/13/2018
|
|
|-
|2018||35||Pifeltro||Doravirine||[[Doravirine]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pifeltro Pifeltro]||8/30/2018
|
|
|-
|2018||34||Xerava||Eravacycline||[[Eravacycline]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Xerava Xerava]||8/27/2018
|
|
|-
|2018||33||Takhzyro||Lanadelumab||[[Lanadelumab]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Takhzyro Takhzyro]||8/23/2018
|
|
|-
|2018||32||Oxervate||Cenegermin-bkbj||[[Cenegermin-bkbj]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Oxervate Oxervate]||8/22/2018
|
|
|-
|2018||31||Diacomit||Stiripentol||[[Stiripentol]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Diacomit Diacomit]||8/20/2018
|
|
|-
|2018||30||Galafold||Migalastat||[[Migalastat]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Galafold Galafold]||8/10/2018
|
|
|-
|2018||29||Annovera||Segesterone acetate and ethinyl estradiol vaginal system||[[Segesterone acetate and ethinyl estradiol vaginal system]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Annovera Annovera]||8/10/2018
|
|
|-
|2018||28||Onpattro||Patisiran||[[Patisiran]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Onpattro Onpattro]||8/10/2018
|
|
|-
|2018||27||Poteligeo||Mogamulizumab||[[Mogamulizumab]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Poteligeo Poteligeo]||8/8/2018
|
|
|-
|2018||26||Mulpleta||Lusutrombopag||[[Lusutrombopag]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Mulpleta Mulpleta]||7/31/2018
|
|
|-
|2018||25||Omegaven||Fish oil triglycerides||[[Fish oil triglycerides]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Omegaven Omegaven]||7/27/2018
|Bhavya
|In progress
|-
|2018||24||Orilissa||Elagolix||[[Elagolix]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Orilissa Orilissa]||7/23/2018
|
|
|-
|2018||23||Krintafel||Tafenoquine||[[Tafenoquine]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Krintafel Krintafel]||7/20/2018
|
|
|-
|2018||22||Tibsovo||Ivosidenib||[[Ivosidenib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tibsovo Tibsovo]||7/20/2018
|
|
|-
|2018||21||TPOXX||Tecovirimat||[[Tecovirimat]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=TPOXX TPOXX]||7/13/2018
|
|
|-
|2018||20||Braftovi||Encorafenib||[[Encorafenib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Braftovi Braftovi]||6/27/2018
|
|
|-
|2018||19||Mektovi||Binimetinib||[[Binimetinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Mektovi Mektovi]||6/27/2018
|
|
|-
|2018||18||Zemdri||Plazomicin||[[Plazomicin]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Zemdri Zemdri]||6/25/2018
|
|
|-
|2018||17||Epidioloex||Cannabidiol||[[Cannabidiol]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Epidioloex Epidioloex]||6/25/2018
|
|
|-
|2018||16||Moxidectin||Moxidectin||[[Moxidectin]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Moxidectin Moxidectin]||6/13/2018
|
|
|-
|2018||15||Olumiant||Baricitinib||[[Baricitinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Olumiant Olumiant]||5/31/2018
|
|
|-
|2018||14||Palynziq||Pegvaliase-pqpz||[[Pegvaliase-pqpz]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Palynziq Palynziq]||5/24/2018
|
|
|-
|2018||13||Doptelet||Avatrombopag||[[Avatrombopag]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Doptelet Doptelet]||5/21/2018
|
|
|-
|2018||12||Lokelma||Sodium zirconium cyclosilicate||[[Sodium zirconium cyclosilicate]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lokelma Lokelma]||5/18/2018
|
|
|-
|2018||11||Aimovig||Erenumab-aooe||[[Erenumab-aooe]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Aimovig Aimovig]||5/17/2018
|
|
|-
|2018||10||Lucemyra||Lofexidine hydrochloride||[[Lofexidine hydrochloride]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lucemyra Lucemyra]||5/16/2018
|
|
|-
|2018||9||Akynzeo||Fosnetupitant and palonosetron||[[Fosnetupitant and palonosetron]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Akynzeo Akynzeo]||4/19/2018
|
|
|-
|2018||8||Crysvita||Burosumab-twza||[[Burosumab-twza]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Crysvita Crysvita]||4/17/2018
|
|
|-
|2018||7||Tavalisse||Fostamatinib||[[Fostamatinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tavalisse Tavalisse]||4/17/2018
|
|
|-
|2018||6||Ilumya||Tildrakizumab||[[Tildrakizumab]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ilumya Ilumya]||3/20/2018
|
|
|-
|2018||5||Trogarzo||Ibalizumab-uiyk||[[Ibalizumab-uiyk]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Trogarzo Trogarzo]||3/6/2018
|
|
|-
|2018||4||Erleada||Apalutamide||[[Apalutamide]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Erleada Erleada]||2/14/2018
|
|
|-
|2018||3||Symdeko||Tezacaftor/ivacaftor||[[Tezacaftor/ivacaftor]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Symdeko Symdeko]||2/12/2018
|
|
|-
|2018||2||Biktarvy||Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate||[[Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Biktarvy Biktarvy]||2/7/2018
|
|
|-
|2018||1||Lutathera||Lutetium lu 177 dotatate||[[Lutetium lu 177 dotatate]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lutathera Lutathera]||1/26/2018
|
|
|}
--->
</div>